These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29064615)

  • 1. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.
    Lehmann M; Ashworth K; Manco-Johnson M; Di Paola J; Neeves KB; Ng CJ
    J Thromb Haemost; 2018 Jan; 16(1):104-115. PubMed ID: 29064615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of Patients with Symptomatic Low von Willebrand Factor from Those with Asymptomatic Low von Willebrand Factor.
    Grabowski EF; Van Cott EM; Bornikova L; Boyle DC; Silva RL
    Thromb Haemost; 2020 May; 120(5):793-804. PubMed ID: 32369850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
    Guddati AK; Rosovsky RP; Van Cott EM; Kuter DJ
    Int J Lab Hematol; 2019 Jun; 41(3):325-330. PubMed ID: 30735311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
    Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
    Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow-chamber system.
    Nogami K; Ogiwara K; Yada K; Shida Y; Takeyama M; Yaoi H; Minami H; Furukawa S; Hosokawa K; Shima M
    J Thromb Haemost; 2016 Apr; 14(4):667-74. PubMed ID: 27061057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a strain rate gradient microfluidic device to von Willebrand's disease screening.
    Brazilek RJ; Tovar-Lopez FJ; Wong AKT; Tran H; Davis AS; McFadyen JD; Kaplan Z; Chunilal S; Jackson SP; Nandurkar H; Mitchell A; Nesbitt WS
    Lab Chip; 2017 Jul; 17(15):2595-2608. PubMed ID: 28660968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the diagnosis and management of type 1 von Willebrand disease.
    Castaman G; Rodeghiero F
    Expert Rev Hematol; 2011 Feb; 4(1):95-106. PubMed ID: 21322782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
    Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
    J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.
    Favaloro EJ; Kershaw G; Bukuya M; Hertzberg M; Koutts J
    Haemophilia; 2001 Mar; 7(2):180-9. PubMed ID: 11260278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
    Vinayagam S; Simons LR; Chowdary P; Thurlow P; Brooks SV; Riddell AF
    Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.
    Atiq F; Schütte LM; Looijen AEM; Boender J; Cnossen MH; Eikenboom J; de Maat MPM; Kruip MJHA; Leebeek FWG
    Blood Adv; 2019 Dec; 3(24):4147-4154. PubMed ID: 31834934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to low-dose desmopressin by a subcutaneous route in children with type 1 von Willebrand disease.
    Akin M
    Hematology; 2013 Mar; 18(2):115-8. PubMed ID: 23321055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
    Michiels JJ; Smejkal P; Penka M; Batorova A; Pricangova T; Budde U; Vangenechten I; Gadisseur A
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):518-531. PubMed ID: 27443694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease.
    Schmidt DE; Bruzelius M; Majeed A; Odeberg J; Holmström M; Ågren A
    Thromb Haemost; 2017 Jul; 117(8):1528-1533. PubMed ID: 28692107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
    J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.